Pamela G. Marrone - 24 Mar 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC

Role: Director
Signature: /s/ Linda V. Moore, as attorney-in-fact
Issuer symbol: N/A
Transactions as of: 24 Mar 2022
Net transactions value: -$9,228
Form type: 4
Filing time: 28 Mar 2022, 17:40:43 UTC
Previous filing: 18 Jan 2022
Next filing: 23 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBII	Common Stock	Options Exercise	$16,000	+20,000	+0.9%	$0.8000	2,243,363	24 Mar 2022	Direct
transaction	MBII	Common Stock	Sale	$25,228	-22,728	-1%	$1.11	2,220,635	24 Mar 2022	Direct	F1, F2
holding	MBII	Common Stock						6,442	24 Mar 2022	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBII	Stock Option (Right to buy)	Options Exercise	$0	-20,000	-46%	$0.000000	23,320	24 Mar 2022	Common Stock	20,000	$0.8000	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3	Ownership is held by Florence H. Marrone TOD Pamela G. Marrone.
F4	The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months.